These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26348642)

  • 21. Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic.
    Mir MA; Kapoor P; Kumar S; Pandey S; Dispenzieri A; Lacy MQ; Dingli D; Hogan W; Buadi F; Hayman S; Gandhi M; Gertz MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):349-357.e2. PubMed ID: 25958193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.
    Scholl S; Klink A; Mügge LO; Schilling K; Höffken K; Sayer HG
    Transfusion; 2005 Oct; 45(10):1676-83. PubMed ID: 16181220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility.
    Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Treleaven J
    Bone Marrow Transplant; 1996 Jul; 18(1):151-6. PubMed ID: 8832008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning.
    Watz E; Remberger M; Ringden O; Lundahl J; Ljungman P; Mattsson J; Wikman A; Uhlin M
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):264-71. PubMed ID: 24274982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia.
    Vela-Ojeda J; García-Ruiz Esparza MA; Tripp-Villanueva F; Ayala-Sánchez M; Delgado-Lamas JL; Garcés-Ruiz O; Rubio-Jurado B; Montiel-Cervantes L; Sánchez-Cortés E; García-Chavez J; Xolotl-Castillo M; Rosas-Cabral A; Salazar-Exaire D; Galindo-Rodríguez G; Aviña-Zubieta A
    Stem Cells Dev; 2004 Oct; 13(5):571-9. PubMed ID: 15588514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
    Kekre N; Tokessy M; Mallick R; McDiarmid S; Huebsch L; Bredeson C; Allan D; Tay J; Tinmouth A; Sheppard D
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet and Red Blood Cell Transfusions and Risk of Acute Graft-versus-Host Disease after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    Gjærde LK; Sørensen ALT; von Stemann JH; Fischer-Nielsen A; Hansen MB; Sengeløv H; Ostrowski SR
    Transplant Cell Ther; 2021 Oct; 27(10):866.e1-866.e9. PubMed ID: 34252580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with the avoidance of red blood cell transfusion after hematopoietic stem cell transplantation.
    Kekre N; Christou G; Mallick R; Tokessy M; Tinmouth A; Tay J; Allan DS
    Transfusion; 2012 Sep; 52(9):2049-54. PubMed ID: 22321053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning.
    Worel N; Böhm A; Rabitsch W; Leitner G; Mitterbauer M; Kalhs P; Mayr WR; Schwartz D; Greinix HT
    Transfusion; 2012 Jun; 52(6):1348-53. PubMed ID: 22128859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor. Comparable results to transplants from HLA-identical related donors in adults with acute leukaemia and myelodysplastic syndromes.
    Sebrango A; Vicuña I; de Laiglesia A; Millán I; Bautista G; Martín-Donaire T; Regidor C; Cabrera R; Fernandez MN
    Best Pract Res Clin Haematol; 2010 Jun; 23(2):259-74. PubMed ID: 20837338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience.
    Ruiz-Argüelles GJ; López-Martínez B; Gómez-Rangel D; Estrada E; Marín-López A; Bravo-Hernández G; Manuel Hernández J
    Hematology; 2003 Jun; 8(3):151-4. PubMed ID: 12745648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic transplantation for myelodysplastic syndrome (MDS).
    Ingram W; Lim ZY; Mufti GJ
    Blood Rev; 2007 Mar; 21(2):61-71. PubMed ID: 16759774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome].
    Zhao T; Huang X; Liu D; Wang J; Zhang X; Wang Y; Han W; Chen H; Chen Y; Wang F; Liu K; Xu L
    Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):89-93. PubMed ID: 24767157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation.
    Malfuson JV; Amor RB; Bonin P; Rodet M; Boccaccio C; Pautas C; Kuentz M; Cordonnier C; Noizat-Pirenne F; Maury S
    Vox Sang; 2007 Jan; 92(1):85-9. PubMed ID: 17181595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies.
    Helbig G; Stella-Holowiecka B; Wojnar J; Krawczyk M; Krzemien S; Wojciechowska-Sadus M; Markiewicz M; Wylezol I; Kopera M; Holowiecki J
    Ann Hematol; 2007 Sep; 86(9):677-83. PubMed ID: 17486341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical observation of factors in the efficacy of blood component transfusion in patients following hematopoietic stem cell transplantation.
    Zhang X; Xiao Y; Ran Q; Liu Y; Duan Q; Duan H; Ye X; Li Z
    PLoS One; 2012; 7(5):e36912. PubMed ID: 22701516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993-2010): factors that predict intensity and time to transfusion independence.
    Griffith LM; VanRaden M; Barrett AJ; Childs RW; Fowler DH; Kang EM; Tisdale JF; Klein HG; Stroncek DF
    Transfusion; 2019 Jan; 59(1):303-315. PubMed ID: 30362577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.